Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications

Baslan, T., Morris, J. P., Zhao, Z., Reyes, J., Ho, Y.-J., Tsanov, K. M., Bermeo, J., Tian, S., Zhang, S., Askan, G., Yavas, A., Lecomte, N., Erakky, A., Varghese, A. M., Zhang, A., Kendall, J., Ghiban, E., Chorbadjiev, L., Wu, J., & Lowe, S. W. (2022). Ordered and deterministic cancer genome evolution after p53 loss. Nature. https://doi.org/10.1038/s41586-022-05082-5. Article 7924.

Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (2021). Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications, 12(1), 7244. https://doi.org/10.1038/s41467-021-27472-5

Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., Blucher, A., Borate, U., Braun, T. P., Brown, J., Bryant, J., Burke, R., Carlos, A., Chang, B. H., Cho, H. J., & Tyner, J. W. (2022). Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell, 40(8), 850-864.e9. https://doi.org/10.1016/j.ccell.2022.07.002

Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C.-E., Schreiber, A. W., Feng, J., Phillips, K., Wang, P. P. S., Ha, T., Homan, C. C., King-Smith, S. L., Rawlings, L., Vakulin, C., Dubowsky, A., Burdett, J., Moore, S., McKavanagh, G., & Scott, H. S. (2020). RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 4(6), 1131–1144. https://doi.org/10.1182/bloodadvances.2019000901

Busque, L., Buscarlet, M., Mollica, L., & Levine, R. L. (2018). Concise review: age-related clonal hematopoiesis: stem cells tempting the devil. Stem Cells, 36(9), 1287–1294. https://doi.org/10.1002/stem.2845

Cancer Genome Atlas Research Network, Ley, T. J., Miller, C., Ding, L., Raphael, B. J., Mungall, A. J., Robertson, A. G., Hoadley, K., Triche, T. J., Laird, P. W., Baty, J. D., Fulton, L. L., Fulton, R., Heath, S. E., Kalicki-Veizer, J., Kandoth, C., Klco, J. M., Koboldt, D. C., Kanchi, K.-L., & Eley, G. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine, 368(22), 2059–2074. https://doi.org/10.1056/NEJMoa1301689

Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd839. Article 7.

Carter, B., & Zhao, K. (2021). The epigenetic basis of cellular heterogeneity. Nature Reviews Genetics. https://doi.org/10.1038/s41576-020-00300-0. Article 4.

Cerrano, M., Duchmann, M., Kim, R., Vasseur, L., Hirsch, P., Thomas, X., Quentin, S., Pasanisi, J., Passet, M., Rabian, F., Rahmé, R., Lengliné, E., Raffoux, E., Dhédin, N., Sébert, M., Maarek, O., Raimbault, A., Celli-Lebras, K., Adès, L., & Itzykson, R. (2021). Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia. https://doi.org/10.1038/s41375-020-0932-8. Article 3.

Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G. J., Meissner, A., Issa, J.-P.J., Godley, L. A., Li, W., & Goodell, M. A. (2012). Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44(1), 23–31. https://doi.org/10.1038/ng.1009

Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E., Rohde, C., Müller-Tidow, C., Geffers, R., Göhring, G., Ganser, A., Thol, F., & Heuser, M. (2016). Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia. https://doi.org/10.1038/leu.2016.71. Article 8.

Chen, Y.-L., Tang, C., Zhang, M.-Y., Huang, W.-L., Xu, Y., Sun, H.-Y., Yang, F., Song, L.-L., Wang, H., Mu, L.-L., Li, M.-H., Zheng, W.-W., Miao, Y., Ding, L.-X., Li, B.-S., Shen, S.-H., Liu, S.-L., Li, H., Zhu, Z.-Q., & Zhou, B.-B.S. (2019). Blocking ATM-dependent NF-κB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia. Leukemia. https://doi.org/10.1038/s41375-019-0458-0. Article 10.

Cocciardi, S., Dolnik, A., Kapp-Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnöder, T. M., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Teleanu, V., Göhring, G., Thol, F., Heuser, M., Ganser, A., Weber, D., & Döhner, K. (2019). Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 10(1), 2031. https://doi.org/10.1038/s41467-019-09745-2

Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences, 111(7), 2548–2553. https://doi.org/10.1073/pnas.1324297111

Cucchi, D. G. J., Polak, T. B., Ossenkoppele, G. J., Uyl–De Groot, C. A., Cloos, J., Zweegman, S., & Janssen, J. J. W. M. (2021). Two decades of targeted therapies in acute myeloid leukemia. Leukemia, 35(3), Article 3. https://doi.org/10.1038/s41375-021-01164-x

Damm, F., Mylonas, E., Cosson, A., Yoshida, K., Della Valle, V., Mouly, E., Diop, M., Scourzic, L., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., Kikushige, Y., Davi, F., Lambert, J., Gautheret, D., Merle-Béral, H., Sutton, L., Dessen, P., & Bernard, O. A. (2014). Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discovery, 4(9), 1088–1101. https://doi.org/10.1158/2159-8290.CD-14-0104

Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019). Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia, 33(2), 299–312.

Davis, A., Gao, R., & Navin, N. (2017). Tumor evolution: Linear, branching, neutral or punctuated? Biochimica Et Biophysica Acta, 1867(2), 151–161. https://doi.org/10.1016/j.bbcan.2017.01.003

Degos, L., & Wang, Z. Y. (2001). All trans retinoic acid in acute promyelocytic leukemia. Oncogene, 20(49), 7140–7145. https://doi.org/10.1038/sj.onc.1204763

DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., Koller, E., Havelange, V., Leber, B., Esteve, J., Wang, J., Pejsa, V., Hájek, R., Porkka, K., Illés, Á., & Pratz, K. W. (2020). Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 383(7), 617–629. https://doi.org/10.1056/NEJMoa2012971

Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., & DiPersio, J. F. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 481(7382), 506–510. https://doi.org/10.1038/nature10738

Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., & Löwenberg, B. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12), 1345–1377. https://doi.org/10.1182/blood.2022016867

Döhner, H., Wei, A. H., & Löwenberg, B. (2021). Towards precision medicine for AML. Nature Reviews Clinical Oncology, 18(9), 577–590. https://doi.org/10.1038/s41571-021-00509-w

Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015). Acute myeloid leukemia. New England Journal of Medicine, 373(12), 1136–1152. https://doi.org/10.1056/NEJMra1406184

Duan, C.-W., Shi, J., Chen, J., Wang, B., Yu, Y.-H., Qin, X., Zhou, X.-C., Cai, Y.-J., Li, Z.-Q., Zhang, F., Yin, M.-Z., Tao, Y., Mi, J.-Q., Li, L.-H., Enver, T., Chen, G.-Q., & Hong, D.-L. (2014). Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell, 25(6), 778–793. https://doi.org/10.1016/j.ccr.2014.04.015

Duchmann, M., Laplane, L., & Itzykson, R. (2021). Clonal architecture and evolutionary dynamics in acute myeloid leukemias. Cancers, 13(19), 4887. https://doi.org/10.3390/cancers13194887

Ferrando, A. A., & López-Otín, C. (2017). Clonal evolution in leukemia. Nature Medicine. https://doi.org/10.1038/nm.4410. Article 10.

Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., & McCarroll, S. A. (2014). Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New England Journal of Medicine, 371(26), 2477–2487. https://doi.org/10.1056/NEJMoa1409405

Gibson, C. J., Lindsley, R. C., Tchekmedyian, V., Mar, B. G., Shi, J., Jaiswal, S., Bosworth, A., Francisco, L., He, J., Bansal, A., Morgan, E. A., Lacasce, A. S., Freedman, A. S., Fisher, D. C., Jacobsen, E., Armand, P., Alyea, E. P., Koreth, J., Ho, V., & Ebert, B. L. (2017). Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35(14), 1598–1605. https://doi.org/10.1200/JCO.2016.71.6712

Gilliland, D. G., & Griffin, J. D. (2002). The roles of FLT3 in hematopoiesis and leukemia. Blood, 100(5), 1532–1542. https://doi.org/10.1182/blood-2002-02-0492

Goto, E., Tomita, A., Hayakawa, F., Atsumi, A., Kiyoi, H., & Naoe, T. (2011). Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, 118(6), 1600–1609. https://doi.org/10.1182/blood-2011-01-329433

Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature. https://doi.org/10.1038/nature10762. Article 7381.

Greif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Kerbs, P., Jurinovic, V., Schumacher, D., Pastore, F., Bräundl, K., Zellmeier, E., Ksienzyk, B., Konstandin, N. P., Schneider, S., Graf, A., & Spiekermann, K. (2018). Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients. Clinical Cancer Research, 24(7), 1716–1726. https://doi.org/10.1158/1078-0432.CCR-17-2344

Hahn, C. N., Chong, C.-E., Carmichael, C. L., Wilkins, E. J., Brautigan, P. J., Li, X.-C., Babic, M., Lin, M., Carmagnac, A., Lee, Y. K., Kok, C. H., Gagliardi, L., Friend, K. L., Ekert, P. G., Butcher, C. M., Brown, A. L., Lewis, I. D., To, L. B., Timms, A. E., & Scott, H. S. (2011). Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature Genetics. https://doi.org/10.1038/ng.913. Article 10.

Hausser, J., & Alon, U. (2020). Tumour heterogeneity and the evolutionary trade-offs of cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-020-0241-6. Article 4.

Hirsch, P., Zhang, Y., Tang, R., Joulin, V., Boutroux, H., Pronier, E., Moatti, H., Flandrin, P., Marzac, C., Bories, D., Fava, F., Mokrani, H., Betems, A., Lorre, F., Favier, R., Féger, F., Mohty, M., Douay, L., Legrand, O., & Delhommeau, F. (2016). Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nature Communications. https://doi.org/10.1038/ncomms12475. Article 1.

Hochhaus, A., Kreil, S., Corbin, A. S., La Rosée, P., Müller, M. C., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N. C. P., Berger, U., Gschaidmeier, H., Druker, B. J., & Hehlmann, R. (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. https://doi.org/10.1038/sj.leu.2402741. Article 11.

Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C.-E., Menssen, H. D., Kantarjian, H., O’Brien, S. G., & Druker, B. J. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine, 376(10), 917–927. https://doi.org/10.1056/NEJMoa1609324

Itzykson, R., Duployez, N., Fasan, A., Decool, G., Marceau-Renaut, A., Meggendorfer, M., Jourdan, E., Petit, A., Lapillonne, H., Micol, J.-B., Cornillet-Lefebvre, P., Ifrah, N., Leverger, G., Dombret, H., Boissel, N., Haferlach, T., & Preudhomme, C. (2018). Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood, 132(2), 187–196. https://doi.org/10.1182/blood-2018-03-837781

Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., & Ebert, B. L. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371(26), 2488–2498. https://doi.org/10.1056/NEJMoa1408617

Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012). Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science Translational Medicine, 4(149), 149ra118-149ra118. https://doi.org/10.1126/scitranslmed.3004315

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., Leiserson, M. D. M., Miller, C. A., Welch, J. S., Walter, M. J., Wendl, M. C., Ley, T. J., Wilson, R. K., Raphael, B. J., & Ding, L. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502(7471), 333–339. https://doi.org/10.1038/nature12634

Klco, J. M., Miller, C. A., Griffith, M., Petti, A., Spencer, D. H., Ketkar-Kulkarni, S., Wartman, L. D., Christopher, M., Lamprecht, T. L., Helton, N. M., Duncavage, E. J., Payton, J. E., Baty, J., Heath, S. E., Griffith, O. L., Shen, D., Hundal, J., Chang, G. S., Fulton, R., & Ley, T. J. (2015). Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA, 314(8), 811–822. https://doi.org/10.1001/jama.2015.9643

Koeffler, H. P., & Leong, G. (2017). Preleukemia: One name, many meanings. Leukemia. https://doi.org/10.1038/leu.2016.364. Article 3.

Koya, J., Kataoka, K., Sato, T., Bando, M., Kato, Y., Tsuruta-Kishino, T., Kobayashi, H., Narukawa, K., Miyoshi, H., Shirahige, K., & Kurokawa, M. (2016). DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nature Communications, 7(1), 10924. https://doi.org/10.1038/ncomms10924

Lal, R., Lind, K., Heitzer, E., Ulz, P., Aubell, K., Kashofer, K., Middeke, J. M., Thiede, C., Schulz, E., Rosenberger, A., Hofer, S., Feilhauer, B., Rinner, B., Svendova, V., Schimek, M. G., Rücker, F. G., Hoefler, G., Döhner, K., Zebisch, A., & Sill, H. (2017). Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood, 129(18), 2587–2591. https://doi.org/10.1182/blood-2016-11-751008

Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., Wan, Y., Zhang, W., Shukla, S. A., Vartanov, A., Fernandes, S. M., Saksena, G., Cibulskis, K., Tesar, B., Gabriel, S., & Wu, C. J. (2013). Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell, 152(4), 714–726. https://doi.org/10.1016/j.cell.2013.01.019

Landau, D. A., Clement, K., Ziller, M. J., Boyle, P., Fan, J., Gu, H., Stevenson, K., Sougnez, C., Wang, L., Li, S., Kotliar, D., Zhang, W., Ghandi, M., Garraway, L., Fernandes, S. M., Livak, K. J., Gabriel, S., Gnirke, A., Lander, E. S., & Wu, C. J. (2014). Locally disordered methylation forms the basis of intra-tumor methylome variation in chronic lymphocytic leukemia. Cancer Cell, 26(6), 813–825. https://doi.org/10.1016/j.ccell.2014.10.012

Levine, A. J., Jenkins, N. A., & Copeland, N. G. (2019). The roles of initiating truncal mutations in human cancers: The order of mutations and tumor cell type matters. Cancer Cell, 35(1), 10–15. https://doi.org/10.1016/j.ccell.2018.11.009

Li, B., Brady, S. W., Ma, X., Shen, S., Zhang, Y., Li, Y., Szlachta, K., Dong, L., Liu, Y., Yang, F., Wang, N., Flasch, D. A., Myers, M. A., Mulder, H. L., Ding, L., Liu, Y., Tian, L., Hagiwara, K., Xu, K., & Zhang, J. (2020). Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 135(1), 41–55. https://doi.org/10.1182/blood.2019002220

Li, S., Garrett-Bakelman, F. E., Chung, S. S., Sanders, M. A., Hricik, T., Rapaport, F., Patel, J., Dillon, R., Vijay, P., Brown, A. L., Perl, A. E., Cannon, J., Bullinger, L., Luger, S., Becker, M., Lewis, I. D., To, L. B., Delwel, R., Löwenberg, B., & Mason, C. E. (2016). Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 22(7), 792–799. https://doi.org/10.1038/nm.4125

Ling, S., Hu, Z., Yang, Z., Yang, F., Li, Y., Lin, P., Chen, K., Dong, L., Cao, L., Tao, Y., Hao, L., Chen, Q., Gong, Q., Wu, D., Li, W., Zhao, W., Tian, X., Hao, C., Hungate, E. A., & Wu, C.-I. (2015). Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proceedings of the National Academy of Sciences, 112(47), E6496–E6505. https://doi.org/10.1073/pnas.1519556112

Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., & Platzbecker, U. (2013). Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369(2), 111–121. https://doi.org/10.1056/NEJMoa1300874

Lyne, A.-M., Laplane, L., & Perié, L. (2021). To portray clonal evolution in blood cancer, count your stem cells. Blood, 137(14), 1862–1870. https://doi.org/10.1182/blood.2020008407

Mantovani, F., Collavin, L., & Del Sal, G. (2019). Mutant p53 as a guardian of the cancer cell. Cell Death & Differentiation. https://doi.org/10.1038/s41418-018-0246-9. Article 2.

McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell, 168(4), 613–628. https://doi.org/10.1016/j.cell.2017.01.018

McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., Lasater, E. A., DeFilippis, R., Peretz, C. A. C., McGary, L. H. F., Deihimi, S., Logan, A. C., Luger, S. M., Shah, N. P., Carroll, M., & Perl, A. E. (2019). Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discovery, 9(8), 1050–1063. https://doi.org/10.1158/2159-8290.cd-18-1453

Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006). Cancer as an evolutionary and ecological process. Nature Reviews Cancer. https://doi.org/10.1038/nrc2013. Article 12.

Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., Ksienzyk, B., Zellmeier, E., Hartmann, L., Greif, P. A., Fiegl, M., Subklewe, M., Bohlander, S. K., Krug, U., Faldum, A., On behalf of the AMLCG Study Group. (2016). Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood, 128(5), 686–698. https://doi.org/10.1182/blood-2016-01-693879

Miles, L. A., Bowman, R. L., Merlinsky, T. R., Csete, I. S., Ooi, A. T., Durruthy-Durruthy, R., Bowman, M., Famulare, C., Patel, M. A., Mendez, P., Ainali, C., Demaree, B., Delley, C. L., Abate, A. R., Manivannan, M., Sahu, S., Goldberg, A. D., Bolton, K. L., Zehir, A., & Levine, R. L. (2020). Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature, 587(7834), 477–482. https://doi.org/10.1038/s41586-020-2864-x

Mills, C. C., Kolb, E. A., & Sampson, V. B. (2018). Development of chemotherapy with cell cycle inhibitors for adult and pediatric cancer therapy. Cancer Research, 78(2), 320–325. https://doi.org/10.1158/0008-5472.CAN-17-2782

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., & Levine, R. L. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20(1), 11–24. https://doi.org/10.1016/j.ccr.2011.06.001

Morita, K., Wang, F., Jahn, K., Hu, T., Tanaka, T., Sasaki, Y., Kuipers, J., Loghavi, S., Wang, S. A., Yan, Y., Furudate, K., Matthews, J., Little, L., Gumbs, C., Zhang, J., Song, X., Thompson, E., Patel, K. P., Bueso-Ramos, C. E., & Takahashi, K. (2020). Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nature Communications, 11(1), 5327. https://doi.org/10.1038/s41467-020-19119-8

Murphy, T., Zou, J., Daher-Reyes, G. S., Arruda, A., Gupta, V., McNamara, C. J., Minden, M. D., Schimmer, A. D., Sibai, H., Yee, K. W. L., Korulla, M., Stockley, T., Kamel-Reid, S., Maze, D., Tierens, A., Bratman, S. V., Schuh, A. C., & Chan, S. M. (2019). Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. Blood Advances, 3(15), 2307–2311. https://doi.org/10.1182/bloodadvances.2019000306

Nangalia, J., Nice, F. L., Wedge, D. C., Godfrey, A. L., Grinfeld, J., Thakker, C., Massie, C. E., Baxter, J., Sewell, D., Silber, Y., Campbell, P. J., & Green, A. R. (2015). DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. https://doi.org/10.3324/haematol.2015.129510. Article 11.

Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., Baxter, E. J., Massie, C. E., Papaemmanuil, E., Menon, S., Godfrey, A. L., Dimitropoulou, D., Guglielmelli, P., Bellosillo, B., Besses, C., Döhner, K., Harrison, C. N., Vassiliou, G. S., Vannucchi, A., & Green, A. R. (2015). Effect of mutation order on myeloproliferative neoplasms. New England Journal of Medicine, 372(7), 601–612. https://doi.org/10.1056/nejmoa1412098

Padella, A., Ghelli Luserna Di Rorà, A., Marconi, G., Ghetti, M., Martinelli, G., & Simonetti, G. (2022). Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-022-01228-0

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., & Campbell, P. J. (2016). Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374(23), 2209–2221. https://doi.org/10.1056/nejmoa1516192

Pellegrino, M., Sciambi, A., Treusch, S., Durruthy-Durruthy, R., Gokhale, K., Jacob, J., Chen, T. X., Geis, J. A., Oldham, W., Matthews, J., Kantarjian, H., Futreal, P. A., Patel, K., Jones, K. W., Takahashi, K., & Eastburn, D. J. (2018). High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Research, 28(9), 1345–1352. https://doi.org/10.1101/gr.232272.117

Peretz, C. A. C., McGary, L. H. F., Kumar, T., Jackson, H., Jacob, J., Durruthy-Durruthy, R., Levis, M. J., Perl, A., Huang, B. J., & Smith, C. C. (2021). Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Advances, 5(5), 1437–1441. https://doi.org/10.1182/bloodadvances.2020003398

Rasmussen, K. D., Jia, G., Johansen, J. V., Pedersen, M. T., Rapin, N., Bagger, F. O., Porse, B. T., Bernard, O. A., Christensen, J., & Helin, K. (2015). Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes & Development, 29(9), 910–922. https://doi.org/10.1101/gad.260174.115

Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laï, J.-L., Philippe, N., Facon, T., Fenaux, P., & Preudhomme, C. (2002). Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100(3), 1014–1018. https://doi.org/10.1182/blood.v100.3.1014

Rothenberg-Thurley, M., Amler, S., Goerlich, D., Köhnke, T., Konstandin, N. P., Schneider, S., Sauerland, M. C., Herold, T., Hubmann, M., Ksienzyk, B., Zellmeier, E., Bohlander, S. K., Subklewe, M., Faldum, A., Hiddemann, W., Braess, J., Spiekermann, K., & Metzeler, K. H. (2018). Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-018-0034-z. Article 7.

Rücker, F. G., Du, L., Luck, T. J., Benner, A., Krzykalla, J., Gathmann, I., Voso, M. T., Amadori, S., Prior, T. W., Brandwein, J. M., Appelbaum, F. R., Medeiros, B. C., Tallman, M. S., Savoie, L., Sierra, J., Pallaud, C., Sanz, M. A., Jansen, J. H., Niederwieser, D., & Döhner, K. (2021). Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. https://doi.org/10.1038/s41375-021-01323-0

Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R., Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., & Ley, T. J. (2014). The R882H DNMT3A mutation associated with AML dominantly inhibits WT DNMT3A by blocking its ability to form active tetramers. Cancer Cell, 25(4), 442–454. https://doi.org/10.1016/j.ccr.2014.02.010

Sallman, D. A., & List, A. (2019). The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood, 133(10), 1039–1048. https://doi.org/10.1182/blood-2018-10-844654

Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J., Skambraks, S., Rücker, F. G., Gaidzik, V. I., Paschka, P., Fiedler, W., Salih, H. R., Wulf, G., Schroeder, T., Lübbert, M., Schlenk, R. F., & Bullinger, L. (2021). Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 137(22), 3093–3104. https://doi.org/10.1182/blood.2020007626

Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., McLeod, J. L., Doedens, M., Medeiros, J. J. F., Marke, R., Kim, H. J., Lee, K., McPherson, J. D., Hudson, T. J., Pan-Leukemia Gene Panel Consortium, T. H., & Dick, J. E. (2014). Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. https://doi.org/10.1038/nature13038. Article 7488.

Simon, L., Spinella, J.-F., Yao, C.-Y., Lavallée, V.-P., Boivin, I., Boucher, G., Audemard, E., Bordeleau, M.-E., Lemieux, S., Hébert, J., & Sauvageau, G. (2020). High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood, 135(21), 1882–1886. https://doi.org/10.1182/blood.2019003357

Smith, C. C., Paguirigan, A., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T., Chin, C.-S., Asthana, S., Olshen, A., Travers, K. J., Wang, S., Levis, M. J., Perl, A. E., Radich, J. P., & Shah, N. P. (2017). Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood, 130(1), 48–58. https://doi.org/10.1182/blood-2016-04-711820

Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004). Mutation of CEBPA in familial acute myeloid leukemia. New England Journal of Medicine, 351(23), 2403–2407. https://doi.org/10.1056/NEJMoa041331

Spencer, D. H., Russler-Germain, D. A., Ketkar, S., Helton, N. M., Lamprecht, T. L., Fulton, R. S., Fronick, C. C., O’Laughlin, M., Heath, S. E., Shinawi, M., Westervelt, P., Payton, J. E., Wartman, L. D., Welch, J. S., Wilson, R. K., Walter, M. J., Link, D. C., DiPersio, J. F., & Ley, T. J. (2017). CpG island hypermethylation mediated by DNMT3A Is a consequence of AML progression. Cell, 168(5), 801-816.e13. https://doi.org/10.1016/j.cell.2017.01.021

Stein, E. M., DiNardo, C. D., Fathi, A. T., Mims, A. S., Pratz, K. W., Savona, M. R., Stein, A. S., Stone, R. M., Winer, E. S., Seet, C. S., Döhner, H., Pollyea, D. A., McCloskey, J. K., Odenike, O., Löwenberg, B., Ossenkoppele, G. J., Patel, P. A., Roshal, M., Frattini, M. G., & Tallman, M. S. (2021). Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study. Blood, 137(13), 1792–1803. https://doi.org/10.1182/blood.2020007233

Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, U., Bryant, J., Burke, R., Carlos, A., Carpenter, R., Carroll, J., Chang, B. H., & Druker, B. J. (2018). Functional genomic landscape of acute myeloid leukaemia. Nature, 562(7728), 526–531. https://doi.org/10.1038/s41586-018-0623-z

van Galen, P., Hovestadt, V., Wadsworth, M. H., II., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., Pinkus, G. S., Pozdnyakova, O., Galinsky, I., Stone, R. M., Graubert, T. A., Shalek, A. K., Aster, J. C., Lane, A. A., & Bernstein, B. E. (2019). Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell, 176(6), 1265-1281.e24. https://doi.org/10.1016/j.cell.2019.01.031

Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., Kandoth, C., Fulton, R. S., McLellan, M. D., Dooling, D. J., Wallis, J. W., Chen, K., Harris, C. C., Schmidt, H. K., Kalicki-Veizer, J. M., & Wilson, R. K. (2012). The origin and evolution of mutations in acute myeloid leukemia. Cell, 150(2), 264–278. https://doi.org/10.1016/j.cell.2012.06.023

Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., Heath, S., Baty, J. D., Klco, J. M., Ding, L., Mardis, E. R., Westervelt, P., DiPersio, J. F., Walter, M. J., Graubert, T. A., & Wilson, R. K. (2015). The role of TP53 mutations in the origin and evolution of therapy-related AML. Nature, 518(7540), 552–555. https://doi.org/10.1038/nature13968

Yang, F., Brady, S. W., Tang, C., Sun, H., Du, L., Barz, M. J., Ma, X., Chen, Y., Fang, H., Li, X., Kolekar, P., Pathak, O., Cai, J., Ding, L., Wang, T., von Stackelberg, A., Shen, S., Eckert, C., Klco, J. M., & Zhou, B.-B.S. (2021). Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer, 2(8), 819–834. https://doi.org/10.1038/s43018-021-00230-8

Zebisch, A., Lal, R., Müller, M., Lind, K., Kashofer, K., Girschikofsky, M., Fuchs, D., Wölfler, A., Geigl, J. B., & Sill, H. (2016). Acute myeloid leukemia with TP53 germ line mutations. Blood, 128(18), 2270–2272. https://doi.org/10.1182/blood-2016-08-732610

Zeng, A. G. X., Bansal, S., Jin, L., Mitchell, A., Chen, W. C., Abbas, H. A., Chan-Seng-Yue, M., Voisin, V., van Galen, P., Tierens, A., Cheok, M., Preudhomme, C., Dombret, H., Daver, N., Futreal, P. A., Minden, M. D., Kennedy, J. A., Wang, J. C. Y., & Dick, J. E. (2022). A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nature Medicine. https://doi.org/10.1038/s41591-022-01819-x. Article 6.

Zhang, H., Savage, S., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., Carlos, A., Henson, R., Lin, C., Searles, R., Ho, H., Lam, Y. L., Sweat, R., Follit, C., Jain, V., & Tyner, J. W. (2019). Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications, 10(1), 244. https://doi.org/10.1038/s41467-018-08263-x